- ASSISTANT PROFESSOR Pharmacology and Systems Therapeutics
- ASSISTANT PROFESSOR Neuroscience
Ph.D., Shanghai Institute of Physiology, Chinese Academy of Sciences
Postdoctoral Fellowship, Yale University School of Medicine
Faculty Fellowship, University of Texas Southwestern Medical Center
- Dr. Han is an Assistant Professor in the Department of Pharmacology and Systems Therapeutics, with a joint appointment in the Department of Neuroscience. The Han Laboratory studies neurophysiological mechanisms of depression and alcohol addiction in rodent models.
Dr. Harold & Golden Lamport Research Award for Excellence in Basic Science Research
Mount Sinai School of Medicine
American College of Neuropsychopharmacology (ACNP)
Rising Star Translational Research Award
Johnson & Johnson and International Mental Health Research Organization (IMHRO)
Young Investigator Award
National Alliance for Research on Schizophrenia and Depression (NARSAD)
ResearchOne of the most fundamental functions of the brain is the capacity to develop adaptive changes in response to environmental stimuli under both physiological and pathophysiological conditions. These neural adaptations can occur at a variety of levels such as at the levels of ion channels, synaptic transmission, and integrative function of neuron and neural network, and they are believed to be responsible for governing behavioral/psychological functioning. Dr. Han’s laboratory is specifically interested in identifying the intrinsic plasticity of ion channels and neuronal excitability, and adaptive changes in neural network, that are induced by psychological stress and alcohol in the dopamine circuit of the ventral tegmental area, an emotion- and reward-related system. Research in Dr. Han’s laboratory focuses on the underlying mechanisms of these neuroadpations and how they mediate behavioral susceptibility and resilience to stress and alcohol in laboratory models of depression and alcohol dependence.
To understand the roles of neuroadaptations in mediating behavioral changes, the laboratory employs an up-down-up methodology: established behavior model - neuroadaptation - molecular/ionic mechanism - molecular/ionic manipulation - validation of neuronal function - behavioral test. The laboratory uses in vivo and in vitro electrophysiological techniques to identify neuroadaptations and investigate molecular/ionic mechanisms, and employs advanced gene manipulation approaches, including viral-mediated gene delivery, local knockouts of interested genes, and optogenetic tools, to conduct molecular/ionic manipulation followed by behavioral assays. The combination of these gene manipulation techniques and neurophysiology offers the laboratory a unique ability to explore the neurophysiological basis of depression and alcoholism.
For more information, visit Ming-Hu Han’s Laboratory of Cellular Neurophysiology.
Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, Ferguson D, Tsai HC, Pomeranz L, Christoffel D, Nectow AR, Ekstrand M, Domingos A, Mazie-Robison M, Mouzon E, Lobo MK, Neve RL, Friedman JM, Russo SJ, Deisseroth K, Nestler EJ, Han MH. Rapid regulation of depression-like behaviors by control of midbrain dopamine neurons. Nature 2013 Jan; 493(7433): 532-536.
Russo SJ, Murrough JW, Han MH, Charney DS, Nestler EJ. Neurobiology of resilience. Nature Neuroscience 2012 Nov; 15(11): 1475-1484.
Koo JW, Mazei-Robison MS, Chaudhury D, Juarez B, LaPlant Q, Ferguson D, Feng J, Sun H, Scobie KN, Damez-Werno D, Crumiller M, Ohnishi YN, Ohnishi YH, Mouzon E, Dietz DM, Lobo MK, Neve RL, Russo SJ, Han MH, Nestler EJ. BDNF is a negative modulator of morphine action. Science 2012 Oct; 338(6103): 124-128.
Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, Heshmati M, Golden SA, Kennedy PJ, Takahashi N, Dietz DM, Mocci G, Gabilondo AM, Hanks J, Umali A, Callado LF, Gallitano AL, Neve RL, Shen L, Buxbaum JD, Han MH, Nestler EJ, Meana JJ, Russo SJ, González-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nature Neuroscience 2012 Sep; 15(9): 1245-1254.
Mazei-Robison MS, Koo JW, Friedman AK, Lansink CS, Robison AJ, Vinish M, Krishnan V, Kim S, Siuta MA, Galli A, Niswender KD, Appasani R, Horvath MC, Neve RL, Worley PF, Snyder SH, Hurd YL, Cheer JF, Han MH, Russo SJ, Nestler EJ. Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Neuron 2011 Dec; 72(6): 977-990.
Cao JL, Covington HE 3rd, Friedman AK, Wilkinson MB, Walsh JJ, Cooper DC, Nestler EJ, Han MH. Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. Journal of Neuroscience 2010 Dec; 30(49): 16453-16458.
Lobo MK, Covington HE, Chaudhury D, Friedman AK, Sun H, Damez-Werno D, Dietz DM, Zaman S, Koo JW, Kennedy PJ, Mouzon E, Mogri M, Neve RL, Deisseroth K, Han MH, Nestler EJ. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 2010 Oct; 330(6002): 385-390.
Cao JL, Vialou VF, Lobo MK, Robison AJ, Neve RL, Cooper DC, Nestler EJ, Han MH. Essential role of the cAMP-cAMP response-element binding protein pathway in opiate-induced homeostatic adaptations of locus coeruleus neurons. Proc Natl Acad Sci U S A 2010 Sep; 107(39): 17011-17016.
Wallace DL, Han MH, Graham DL, Green TA, Vialou V, Iniguez SD, Cao JL, Kirk A, Chakravarty S, Kumar A, Krishnan V, Neve RL, Cooper DC, Bolanos CA, Barrot M, McClung CA, Nestler EJ. CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits. Nature Neuroscience 2009 Feb; 12(2): 200-209.
Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, Laplant Q, Graham A, Lutter M, Lagace DC, Ghose S, Reister R, Tannous P, Green TA, Neve RL, Chakravarty S, Kumar A, Eisch AJ, Self DW, Lee FS, Tamminga CA, Cooper DC, Gershenfeld HK, Nestler EJ. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007 Oct; 131(2): 391-404.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Han did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 12 Room 12-76 (Lab)
1425 Madison Avenue
New York, NY 10029
Icahn Medical Institute Floor 12 Room 12-75B (Office)
1425 Madison Avenue
New York, NY 10029